HDM2005 combination therapy for mantle cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination treatment for mantle cell lymphoma that has come back or not responded to prior therapies. It aims to see if adding HDM2005 to standard care can help people with this type of blood cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have mantle cell lymphoma that has come back or not responded to past treatments, including an anti-CD20 antibody and a BTK inhibitor (or you couldn't take a BTK inhibitor).
- You have at least one tumor that can be measured on a scan.
- You are able to take care of yourself (ECOG performance status 0-1 or 0-2 depending on the study part).
- You have adequate organ and bone marrow function and an expected survival of more than 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of chemotherapy and targeted drugs for people who have just been diagnosed with mantle cell lymphoma and haven't had any prior treatment (except short-term steroids or local radiation). It aims to see if adding newer targeted therapies can help keep the lymphoma in remission.
This trial tests a combination of chemotherapy and targeted therapy as a first treatment for mantle cell lymphoma. It uses special scans (PET-CT) and blood tests (MRD) to guide treatment decisions and aims to improve outcomes while reducing side effects.
This trial tests a combination of medicines to treat newly diagnosed high-risk mantle cell lymphoma (MCL). It may help shrink the lymphoma and improve outcomes, especially for people whose disease has higher-risk features.
This early-phase study tests a combination of venetoclax, lenalidomide, and rituximab in people newly diagnosed with mantle cell lymphoma. It aims to control the lymphoma and see how safe and effective this approach is for newly treated patients.
This trial tests a combination of three drugs—obinutuzumab, zanubrutinib, and lenalidomide—as a first treatment for mantle cell lymphoma. The goal is to see if this approach is safe and effective for patients who have not had prior therapy.
This trial tests a combination of three drugs (glofitamab, orelabrutinib, and bortezomib) for people with high-risk mantle cell lymphoma. The goal is to see if the combination works better than standard treatments, and it may be an option if your lymphoma has not responded well or has certain aggressive features.
Hear when a new Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.